OCX Oncocyte

Oncocyte Announces August Investor Conferences Participation

Oncocyte Announces August Investor Conferences Participation

IRVINE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a molecular diagnostics technology company, today announced that CEO Josh Riggs and CFO Andrea James plan to participate in the following investor conferences in August:

  • 9th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference, August 12-13, 2024. Oncocyte management plans to host meetings with investors.
  • Sidoti Micro-Cap Virtual Conference, August 14-15, 2024. The company is scheduled to present on Wednesday, August 14, from 1:00 PM to 1:30 PM ET in Track 3, as well as participate in one-on-one meetings. To join the presentation, please visit the webcast available online at:

For additional details about the conferences or to schedule a one-on-one meeting with Oncocyte’s management team, please contact your Needham or Sidoti representative, or reach out directly to the company’s IR contact, .

About Oncocyte

Oncocyte is a molecular diagnostics technology company. The Company’s tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit . For more information about our products, please visit the following web pages:

VitaGraft Kidney™ - 


VitaGraft Liver™ - 


GraftAssure™ - 


DetermaIO™ - 


DetermaCNI™ - 

VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.

CONTACT:

Jeff Ramson


PCG Advisory


(646) 863-6893



EN
05/08/2024

Underlying

OCXOncocyte

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Oncocyte

 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Office...

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicineWill provide key regulatory and reimbursement supportWill assist business development efforts and strategic partnerships IRVINE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announces the appointment of Dr. Paul Billings as the company’s Consulting Chief Medical Officer. In this part-time role, he will support a range of strategic and ...

January 8, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA)MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-CodeUp to 20% of patients will have detectable DSA within the first five years post kidney transplant, representing greater than 10,000 patients per year in the US.1 From time of onset of dnDSA, 24% of patients will lose their allograft withi...

January 6, 2025 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetin...

Oncocyte to Participate in “J.P. Morgan Week” and Host Investor Meetings January 13-16, 2025, San Francisco, CA IRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend “J.P. Morgan Week,” coinciding with the 43ʳᵈ Annual J.P. Morgan Healthcare Conference in San Francisco, from January 13-16, 2025. During this period, Oncocyte will host one-on-one meetings with interested investors. Investors wishing to schedule a ...

December 9, 2024 1 EN
Free Trial
OCX ONCOCYTE

Oncocyte Corporation: 1 director

A director at Oncocyte Corporation bought 20,000 shares at 2.290USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

12/09/24 December 9, 2024 1 EN
 PRESS RELEASE
Free
OCX ONCOCYTE

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in N...

Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study IRVINE, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, today announced the publication of favorable data regarding its DetermaCNI™ assay. In a in the journal Acta Neuropathologica Communications, DetermaCNI showed promise as a liquid biopsy method for diagnosing and profiling central nervous system tumors by measuring somatic copy number aberrations (SCNAs) in cerebrospinal fluid. For context, copy number instability (CNI) is a scientifically well-kn...

December 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch